Sangaré K A, Koffi A R, Coulibaly I M, Doulourou C
Laboratoire des rétrovirus, Institut Pasteur de Côte d'Ivoire, Abidjan.
Sante. 1997 Sep-Oct;7(5):303-7.
Blood is generally used for detection of antibodies associated with infections. However, removal of blood samples can be problematic and is painful for the patient. It requires suitable equipment and skilled staff, both of which may be expensive. Some patients refuse to allow removal of blood samples because they find it painful and traumatic. Removal of blood samples from children, newborns, immunocompromised or overweight subjects is often particularly difficult. In addition, some religions forbid the taking of blood samples. Thus, it is necessary to develop alternative, simple, painless methods of sampling body fluids that give results as accurate as those obtained with blood samples. Saliva has been suggested as a possible alternative. Epidemiological studies and other reports have shown that saliva may be of value for the detection of HIV antibodies.
To evaluate the potential of saliva for detection of antibodies and seroconversion.
Section I: Saliva and serum from 1,023 subjects, including 150 AIDS patients, 251 TB patients of known HIV status and 622 subjects from at-risk groups were tested. Sera from subjects with unknown HIV status were systematically tested by Abbott recombinant HIV1/HIV2 EIA. Section II: Saliva and sera were obtained from a population at risk of HIV infection. Two hundred and fifty consenting adults were found to be HIV-negative. Saliva was collected from each subject once per week and tested the same day with the Abbott test pack and Wellcozyme GACELISA. A spot of blood was also collected, dried and tested using the Wellcozyme GACELISA protocol. Whenever a positive result was obtained for any test, a blood sample was taken the same day or as soon as possible, for Western, blot analysis. Saliva was collected with an OMNISAL device (SDS, Vancouver, USA) placed under the tongue. The indicator turned blue when enough fluid had been collected. The device was then removed and the saliva placed in a tube with stabilized product. It was then transferred to a casting tube with a filter.
Section I: Saliva from 96 of 150 AIDS patients (64%) tested positive. Serum from these patients also tested positive for HIV. Thirty-two subjects of the 622 from at-risk groups tested positive for HIV in the Abbott recombinant HIV1/HIV2 EIA with saliva (5.14%). Serum from these subjects also tested positive for HIV in Western blot. However, saliva EIA gave 5 false negative results for patients who tested positive in rapid tests and Western blot. We optimized the procedure and obtained 98.69% sensitivity and 100% specificity. Section II: One individual tested positive in saliva and dried blood spot tests in the fourth week of the study. Western blot using serum samples obtained on the next and following days showed a progressive increase in the intensity of the bands, beginning with P24 and GP160 (Fig. 2).
This study shows that testing saliva is effective for determining HIV status early in seroconversion.
血液通常用于检测与感染相关的抗体。然而,采集血样可能存在问题,且对患者来说很痛苦。这需要合适的设备和技术熟练的工作人员,而这两者可能都很昂贵。一些患者拒绝采集血样,因为他们觉得这很痛苦且有创伤性。从儿童、新生儿、免疫功能低下或超重的受试者身上采集血样通常特别困难。此外,一些宗教禁止采集血样。因此,有必要开发替代的、简单、无痛的体液采样方法,其结果要与血样检测结果一样准确。唾液已被提议作为一种可能的替代方法。流行病学研究和其他报告表明,唾液可能对检测HIV抗体有价值。
评估唾液检测抗体和血清转化的潜力。
第一部分:对1023名受试者的唾液和血清进行检测,其中包括150名艾滋病患者、251名已知HIV感染状况的结核病患者以及622名高危人群。对HIV感染状况未知的受试者的血清通过雅培重组HIV1/HIV2酶免疫测定法进行系统检测。第二部分:从有HIV感染风险的人群中获取唾液和血清。发现250名同意参与的成年人HIV检测呈阴性。每周从每位受试者采集一次唾液,并在当天使用雅培检测试剂盒和Wellcozyme GACELISA进行检测。还采集一滴血,干燥后按照Wellcozyme GACELISA方案进行检测。每当任何一项检测获得阳性结果时,当天或尽快采集血样进行蛋白质印迹分析。使用放置在舌下的OMNISAL装置(美国温哥华SDS公司)采集唾液。当收集到足够的液体时,指示剂会变蓝。然后取出装置,将唾液放入装有稳定产品的试管中。接着将其转移到带有过滤器的浇铸管中。
第一部分:150名艾滋病患者中的96名(64%)的唾液检测呈阳性。这些患者的血清HIV检测也呈阳性。在雅培重组HIV1/HIV2酶免疫测定法中,622名高危人群中的32名受试者唾液HIV检测呈阳性(5.14%)。这些受试者的血清在蛋白质印迹分析中HIV检测也呈阳性。然而,唾液酶免疫测定法对在快速检测和蛋白质印迹分析中呈阳性的患者给出了5例假阴性结果。我们优化了检测程序,获得了98.69%的灵敏度和100%的特异性。第二部分:在研究的第四周,有一名个体唾液和干血斑检测呈阳性。使用接下来几天采集的血清样本进行的蛋白质印迹分析显示,条带强度逐渐增加,从P24和GP160开始(图2)。
本研究表明,检测唾液对于在血清转化早期确定HIV感染状况是有效的。